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Abstract
BACKGROUND: Differentiated thyroid carcinomas (DTC) preserve expression of thyroid stimulating hormone 
receptor (TSHR).
AIM: The aim of our study was to evaluate the expression of mRNA-TSHR in peripheral blood of DTC patients, then 
to correlate the expression with clinical features: Serum thyroglobulin (sTg) value, initial staging and findings from the 
whole body scan (WBS), neck ultrasound (US), and total received dose of radioiodine therapy.
MATERIALS AND METHODS: Forty patients were divided into three groups according to the treatment response: 
Patients with incomplete structural response (TCs), incomplete biochemical response (TCb), and excellent 
responders (TCr). Total RNA was isolated from peripheral blood and used for two-step reverse transcriptase-
PCR with appropriate primers. Relative quantification using the ΔCt and 2–ΔΔCt and method was applied. sTg levels 
were evaluated with chemiluminescent assay. The statistical analysis was performed with Spearman Rank Order 
Correlation.
RESULTS: We found that TCs patients expressed mRNA-TSHR by a 5.37-fold higher level than TCr patients, TCb 
patients expressed TSHR by an 8.88-fold higher level than TCr patients. A significant negative correlation was 
detected between sTg and ΔCt (CtTSHR - CtGAPDH) value (R = −0.475; p < 0.05), and between WBS/US findings and 
ΔCt (R= −0.321; p < 0.05).
CONCLUSION: Our data revealed higher expression of mRNA-TSHR in peripheral blood of TCs and TCb compared 
to TCr patients and analysis revealed a significant correlation between mRNA-TSHR and sTg and US/WBS findings. 
Further studies with larger number of subjects and absolute quantification are needed for understanding the real 
meaning of mRNA-TSHR as a biomarker in DTC.
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Introduction
Thyroid tumors are the most common endocrine 
malignancies, with differentiated thyroid carcinomas 
(DTCs) representing more than 88% of all types of thyroid 
tumors [1], [2], [3], [4]. DTCs preserve expression of TSHR 
and the previous research found that the lower expression 
of TSHR was associated with a poor differentiation of 
thyroid carcinomas and a higher probability for distant 
metastases [4], [5]. Through TSH stimulation TSHR perform 
its own function in thyrocyte proliferation, differentiation 
and normal thyroid development and function. Association 
of higher expression of TSHR in DTC was described, with 
the lower expression of the two mesenchymal markers 
N-cadherin and vimentin, suggesting that the higher 
expression of TSHR inhibited cell invasion and metastasis 
through epithelial-mesenchymal transition [5].
Besides standard diagnostic procedures 
during follow-up suggested by the American and 
European thyroid association guidelines [6], [7], 
new biomarkers in follow-up of DTC could be useful 
especially in patients with elevated antithyroglobulin 
antibodies (aTG), limiting usefulness of immunometric 
chemiluminescent assay in the measurement of serum 
thyroglobulin (sTg), as well as limiting specificity of sTg 
value in patients without ablative radioiodine therapy 
and treated only with lobectomy [8].
New molecular technics enabled evaluation of 
the expression levels of specific transcripts in peripheral 
blood and this method was applied in other solid tumors, 
such as prostate, breast, and colon cancer, as one of 
the methods in the detection of circulating tumor cells 
in peripheral blood [9]. The detection of the circulating 
tumor cells is based on the principle of measurement 
expression of tumor specific transcripts in the blood 
sample [9]. Since Ditkoff et al. [10] reported a possible 
usefulness of RT-PCR molecular technique in the 
detection of thyroid circulating cells in blood samples 
as an indicator of metastatic TC, an increased number 
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of studies on this issue have been published in the past 
few years [11], [12], [13].
Using data from the previous investigations 
in relative quantification of gene expression in other 
malignancies and the previous experiences from 
evaluation of thyroid transcripts, we decided to perform 
a relative gene expression of mRNA-thyrotropin 
receptor (TSHR) gene in patients with DTC [14], [15]. It 
is considered that the presence and higher expression 
of tumor specific transcripts indicate the presence of 
circulating tumor cells.
We have set as an objective in our study to 
evaluate the expression of TSHR gene transcripts in 
patients with DTC, and then to correlate the expression 
with clinical features: Serum thyroglobulin (sTg) value, 
total received dose of radioiodine therapy (RAI), initial 
staging and findings from the whole body scan (WBS), 
and neck ultrasound (US) of DTC patients.
Materials And Methods
Subjects
Blood sampling from 40 patients with DTC 
was performed. In all patients, surgery and ablation 
treatment with radioactive 131I were conducted at 
least 6 months before starting the research. Patients 
were divided into three groups according to blood 
levels of sTg and aTg antibodies (CRM 457, Immulite 
2000; Siemens, Munich, Bavaria, Germany), US neck 
examination and findings from WBS, similar to the 
concept of risk stratification by Tuttle et al. [16]. The 
first group (TCs - 22 patients), consisted of patients 
with incomplete structural response to treatment and 
biochemical relapse of the disease; imaging confirmed 
metastatic spread or loco-regional relapse and elevated 
sTg levels > 0.2 ng/mL. The second group (TCb - 6 
patients) was patients with incomplete biochemical 
response and indeterminate response, with only 
elevated sTg > 0.2 ng/mL, or elevated aTg levels, 
without confirmed and known morphological signs for 
relapse. The third group of patients (TCr - 12 patients) 
had complete structural and biochemical response to 
therapy, excellent responders. The thyroid bed and neck 
lymph nodes were evaluated with ultrasound (US) of 
the neck with linear transducer 7.5–10 MHz. WBS was 
performed after ablative or therapy dose of radioiodine 
(RAI). Planar scan and in some cases single-photon 
emission computed tomography (SPECT/CT) were 
performed on dual-head gamma camera. Scans were 
interpreted by two (more than ten years) experienced 
nuclear medicine physicians. Imaging findings from 
WBS and neck US were scored: (0) if there was no 
remnant tissue and enlarged neck lymph nodes and 
absence of distant metastases, (1) if remnant thyroid 
tissue was detected, (3) if loco-regional relapse and 
local neck involved lymph nodes were detected, and 
(4) if distant metastases were present. Corresponding 
to the histopathology reports from total 40 patients, 
four cases were follicular thyroid carcinoma, 25 typical 
variants of papillary thyroid carcinoma, one papillary 
thyroid carcinoma in thyroglossal duct cyst, one papillary 
microcarcinoma, seven follicular variants of papillary 
thyroid carcinomas, and two Hurtle cell carcinomas. 
The TNM staging system for DTC developed by the 
American Joint Committee on Cancer (AJCC) was 
recorded from the histopathology report, and in 31 of 40 
patients, we found detailed description of initial staging 
according TNM. Of them, 15 patients were classified as 
Stage I, two patients were Stage II, four patients were 
Stage III, one patient was Stage IV, five patients were 
Stage IVa, and four patients were Stage IVc. The study 
was approved by the Ethics Committee of the Medical 
Faculty of Ss Cyril and Methodius University, in Skopje, 
Republic of Macedonia, and a written consent was 
obtained from all subjects enrolled in the research.
RNA extraction procedure and real-time 
polymerase
Chain reaction
The blood samples were drawn from patients in 
standard 3 mL EDTA blood vacutainers; total RNA was 
extracted using commercially available RNA isolation 
kit GenElute™. Total RNA purification kit (Sigma-Aldrich 
Co. LLC, St. Louis, MO, USA) and isolated total RNA 
were used for two-step RT-PCRa with ReadyScript™ 
cDNA Synthesis Mix kit (Sigma-Aldrich), according to 
the manufacturer’s protocols.
Real-time polymerase chain reaction
The PCR step was performed using the 
following primer pairs: TSHR-F 5’-GCT TTT CAG GGA 
CTA TGC AAT GAA-3’ and TSHR-R 5’-AAG GGC AGT 
GAC ACT GGT TTG AGA-3’, targeted to amplify a 
segment spanning exons 6 to 9 (nucleotides 555-767 or 
212 bp) [17]. The ubiquitously expressed GAPDH gene 
was used to confirm RNA extraction and RT-PCR using 
primers GAPDH-F 5’-TTC GTC ATG GGT GTG AAC C-3’ 
and GAPDH-R 5’-GAT GAT GTT CTG GAG AGC CC-3’, 
as previously reported [17], [18]. 2 µl of cDNA was added 
for RT quantitative PCR (qPCR), performed according 
manufacturer’s protocol for Hot FirePol Eva Green qPCR 
Mix Plus (Rox) PCR master mix (Solis BioDyne, Tartu, 
Estonia). The reaction mixture for TSHR was incubated at 
95°C for 15 min, followed by 38 cycles of denaturation at 
95°C for 15 s, annealing at 62°C for 20 s, and elongation 
at 72°C for 20 seconds, and for GAPDH incubated at 
95°C for 15 min, followed by 38 cycles of denaturation 
at 95 °C for 15 seconds, annealing at 57°C for 20 s, and 
elongation at 72°C for 20 s. All samples were analyzed in 
duplicate and in some cases in triplicate.
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Relative quantification method
Relative quantification was applied by 
calculating fold change in the gene expression of TSHR 
target gene, normalized to the endogenous reference 
gene GAPDH. Cycle threshold (Ct), ΔCt, ΔΔCt, and 
normalized relative expression ratio values were 
calculated according to 2-ΔΔCt method, by Livak and 
Schmittgen [14]. According to this method, ΔCtTSHR = 
(average CtTSHR-average CtGAPDH) and then ΔΔCt 
value was calculated using ΔCt value from healthy 
volunteers (HC), from data published previously by 
our group [19], or ΔΔCt = [ΔCt(TC)-ΔCt (HC)] and later 
normalized expression ratio 2–ΔΔCt was applied for fold 
change evaluation [14], [15], [19].
Statistical analysis
Intergroup comparison between average ΔCt 
= (TSHR-GAPDH) values was performed with Mann–
Whitney U-test. Spearman rank order correlation was 
performed to measure the direction and strength of 
the association between mRNA-TSHR and sTg, and 
mRNA-TSHR and total received dose of RAI, as well 
as between mRNA-TSHR and initial stage and mRNA-
TSHR and WBS and neck ultrasound findings.
Results
In 37 of 40 patients, the expression of mRNA-
TSHR was detected. Three patients from the TCs group 
were with undetectable samples for mRNA-TSHR. 
Descriptive analysis of all 40 patients is presented in 
Tables 1-3. We detected that TCs patients expressed 
mRNA-TSHR by a 5.37-fold higher level than TCr 
patients, TCb patients expressed mRNA-TSHR by 
an 8.88-fold higher level than TCr patients, as was 
previously reported in our previous study [19].
Table 3: Descriptive analysis of patients with excellent 
response to treatment (TCr)
TCr Pts ΔCt=(TSHR-GAPDH) sTg(µg/L) RAI (mCi) Stage (TNM)
1 11.21 <0.2 100 IVA
2 17.21 <0.2 102 I
3 11.89 <0.2 94 *n
4 11.015 <0.2 87.3 n
5 12.87 <0.2 100 I
6 11.20 <0.2 100 I
7 10.93 <0.2 0 n
8 10.60 <0.2 243.8 III
9 12.37 <0.2 113 I
10 12.22 <0.2 100 II
11 11.11 <0.2 100 I
12 11.91 <0.2 99.5 I
*n: Missing data about initial stage of the disease.
Further intergroup comparison between 
average ΔCt = (TSHR-GAPDH) values was performed 
and a significant difference was detected between TCs 
and TCr group (Mann–Whitney U-test: Z = −2.231, 
p  0.026) and TCb and TCr group (Mann–Whitney 
U-test: Z = −2.341, p = 0.019) (Figure 1).
Figure 1: Intergroup comparison between average ΔCt = (TSHR-
GAPDH) values. Range of ΔCt = (TSHR-GAPDH) values in three 
groups, patients with incomplete structural response to treatment 
and biochemical relapse of the disease or imaging confirmed 
metastatic spread or loco-regional relapse and elevated sTg levels, 
>0.2 ng/mL (TCs patients); second group was patients with incomplete 
biochemical response and indeterminate response, with only elevated 
sTg (>0.2 ng/mL), or elevated aTg levels, without confirmed and 
known morphological signs for relapse (TCb patients); third group 
of patients had complete structural and biochemical response to 
therapy, excellent responders (TCr). Significant difference in average 
ΔCt = (TSHR-GAPDH) values was detected between TCs and TCr 
group (Mann–Whitney U-test: Z = −2.231, p = 0.026) and TCb and 
TCr group (Mann–Whitney U-test: Z = −2.341, p = 0.019).
Correlation between sTg and ΔCt = (TSHR 
- GAPDH) for all three groups of patients showed a 
Table 1: Descriptive analysis of patients with incomplete 
structural response to treatment and biochemical relapse of 
the disease (TCs group)
TCs Pts ΔCt=TSHR-GAPDH) sTg (µg/L) RAI (mCi) Stage (TNM)
1 10.99 16.1 0 III
2 12.26 > 300 300 IVA
3 13.14 3.51 432.1 n*
4 Undet.* 7.73 130 I
5 9.43 254 804 n
6 8.57 12.9 263 III
7 9.58 0.38 100 I
8 10.41 3.3 252 I
9 12.69 0.19 100 I
10 10.61 231 260 n
11 12.38 >300 0 IVC
12 12.59 0.54 286.7 n
13 11.67 6.48 100 III
14 7.47 117 241 IV
15 5.35 >300 283.5 II
16 9.17 >300 250 n*
17 9.56 43.7 0 IVA
18 6.68 >300 229 IVC
19 4.66 84 0 IVA
20 5.53 >300 0 I
21 Undet.* >300 0 IVC
22 Undet.* >300 100 IVC
*Undet: Undetectable expression levels of the mRNA-TSHR, *n: Missing data about initial stage of the 
disease
Table 2: Descriptive analysis of patients with incomplete 
biochemical response to treatment or indeterminate response 
(TCb group)
TCb Pts ΔCt=TSHR-GAPDH) sTg(µg/L) RAI (mCi) Stage (TNM)
1 10.77 <0.2 50 I 
2 12.56 0.5 102 IVA
3 5.63 0.26 0 I
4 10.31 0.43 105 I
5 4.15 2.5 0 I
6 9.94 0.4 103 n*
*n: Missing data about initial stage of the disease.
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significant negative correlation with Spearman Rank 
Order Correlation (R = −0.475 p < 0.05) (Figure 2). This 
finding suggest that the increased sTg value correlated 
with the lower value of ΔCt = (TSHR-GAPDH) for TSHR 
gene, or higher expression of the evaluated transcripts.
Figure 2: Correlation between sTg and ΔCt = (TSHR - GAPDH) 
for all three groups of patients. sTg values were correlated with 
ΔCt = (TSHR - GAPDH) values from all patients using Spearman 
Rank Order Correlation. Results showed significant negative 
correlation (R = −0.475 p < 0.05).
The analysis of the correlation between RAI 
and ΔCt = (TSHR - GAPDH) showed a weak non-
significant positive correlation with Speаrman Rank 
Order Correlation (R = 0.114, p > 0.05) (Figure 3). Data 
showed that with increase of the total received RAI 
therapy, there was a non-significant increase in the 
ΔCt = (TSHR - GAPDH) for TSHR gene, or increased 
RAI dose correlated with the lower expression levels of 
transcripts for TSHR gene.
Figure 3: Correlation between received total dose of RAI (mCi) and 
value for ΔCt = (TSHR - GAPDH) for TSHR. Received doses of 
radioiodine therapy in milliCuries were correlated with ΔCt = (TSHR 
- GAPDH) values using Spearman Rank Order Correlation. Results 
showed weak non-significant positive correlation (R = 0.114, 
p > 0.05).
Correlation between initial stage of the 
disease according to TNM staging and ΔCt = (TSHR - 
GAPDH) revealed non-significant negative correlation, 
with Spearman Rank Order Correlation (R= −0.0009, 
p > 0.05) (Figure 4). This means that with increase of 
the initial stage of the disease, ΔCt = (TSHR-GAPDH) 
value was non-significantly lowered, or increase 
expression of the transcripts of the TSHR gene.
Final analysis in our study was correlation 
between WBS/US findings and ΔCt = (TSHR-GAPDH), 
resulting with significant a moderate negative 
correlation using Spearman Rank Order Correlation 
(R = −0.321, p < 0.05) (Figure 5). Increase of the 
score from the findings from WBS/US correlated with 
significant lowering of the ΔCt = (TSHR - GAPDH), or 
increase of the score was associated with a significant 
increase of the expression level of TSHR gene 
transcripts.
Figure 4: Correlation between initial stage and ΔCt = (TSHR - 
GAPDH). Initial stages of the disease according TNM staging were 
correlated with ΔCt = (TSHR - GAPDH) using Spearman Rank Order 
Correlation. Results revealed non-significant negative correlation 
(R = −0.0009, p > 0.05).
Figure 5: Correlation between WBS/US findings and ΔCt = (TSHR 
- GAPDH). Radioiodine WBS were analyzed and neck ultrasound 
examinations were performed and findings were scored with: (0) if 
there was no remnant tissue and enlarged neck lymph nodes and 
absence of distant metastases, (1) if remnant thyroid tissue was 
detected, (3) if loco-regional relapse and local neck involved lymph 
nodes were detected, and (4) if distant metastases were present 
and those scores were correlated with ΔCt = (TSHR-GAPDH) using 
Spearman Rank Order Correlation. Results revealed significant 
moderate negative correlation (R= −0.321, p < 0.05).
 A - Basic Sciences Pharmacology
870 https://www.id-press.eu/mjms/index
Discussion
Data from our analysis revealed a higher 
expression level of mRNA-TSHR in peripheral blood 
of TCs and TCb compared to TCr group of patients. In 
only three samples from all TCs patients, expression 
levels were undetectable. This finding may be due to 
dedifferentiation of tumor in the TCs group of patients 
and low expression of the evaluated transcripts for 
the target genes. Correlation of ΔCt value for TSHR 
gene with sTg level indicated a significant negative 
correlation, or in other words, elevation of sTg value 
correlated with an increase in the expression of 
mRNA-TSHR. Increase in expression of mRNA-
TSHR results in lowering ΔCt value representing 
the difference between threshold cycles for the 
amplicons for target gene and reference gene. In DTC 
patients besides sTg level, neck US and WBS are an 
important and standard part of the follow-up routine. 
Evaluated association between US/WBS findings and 
ΔCt value for TSHR gene also revealed a significant 
negative correlation, which means extensiveness of 
the loco-regional status or distant metastatic state 
confirmed with imaging modalities correlated with 
higher expression of mRNA-TSHR. Ringel et al. [20] 
evaluated the expression of mRNA-Tg and they found 
that quantitative detection of circulating mRNA-Tg 
corresponded with the finding from last radioiodine 
WBS. They analyzed and found a positive connection 
of TSH value and expression of mRNA-Tg in patients 
with DTC, and although the exact mechanism was not 
known, they suggested that this relation was due to 
an increased Tg gene transcription under stimulation 
of TSH [20]. The need of new molecular biomarkers 
in diagnosis and follow-up of DTC is important in 
patients with elevated aTg antibodies and in patients 
with lobectomy, without ablative radioiodine therapy, 
which is recommended in low-risk group of patients 
according to the new АТА 2015 guidelines [8], [16]. The 
detection of mRNA of Tg gene was first introduced by 
Ditkoff et al. and the results were encouraging [9], [10], 
initiating many researchers to work in this field, but 
methodology varied significantly among research 
groups in respect of used primers, number of cycles, 
selection of reference gene, and quantification. In 
2002, Gupta et al. [17] concluded that mRNA-TSHR 
could be tumor marker for DTC patients [13]. In 
2004, Chinnappa et al. [18] found that DTC patients 
had a higher rate of mRNA-TSHR expression in the 
peripheral blood than healthy individuals [14]. Wagner 
et al. [21] using RT-PCR detected a higher level of 
mRNA-TSHR in patients with benign thyroid nodules. 
We applied the semi-quantitative analysis using 2-ΔΔCt 
method by Livak [14] in the previous research including 
healthy individuals and DTC patients and detected 
significantly higher expression in TCs and TCb group 
of patients compared to healthy control group [19]. Our 
further analysis was aimed at correlation of expression 
of mRNA-TSHR with sTg values, initial staging, US/
WBS findings and total received RAI therapy. Our 
findings revealed that expression of the transcripts 
corresponded with clinical and laboratory findings in 
the evaluated patients. On the other hand, we found 
non-significant correlation with the initial stage of the 
disease and expression levels. This might be due to 
a great difference in the follow-up period of patients 
which varied from only 1 month to 405 months from 
diagnosis till including in the study. Furthermore, 
there is a possibility of the lower expression of the 
transcripts for TSHR gene in more aggressive variants, 
or development of dedifferentiation of the tumor in the 
evolution of the disease. In light of this explanation 
is the non-significant positive correlation of ΔCt with 
the total dose of RAI therapy, or increased dose 
correlated non-significantly with the lower expression 
of mRNA-TSHR.
Mira Milas et al. have published several 
studies comprising the largest number of patients with 
expression of mRNK-TSHR in DTC cases and found 
that expression levels were lower or undetectable 
in more aggressive forms of thyroid carcinomas 
and dedifferentiation, or mutation of the evaluated 
gene was pointed as a possible reason [22]. Qiu 
et al. [23] investigated the possible role of mRNA-
TSHR measurement in peripheral blood preoperative 
detection of microcarcinomas in suspicious nodules 
smaller than 1 cm. They evaluated mRNA-TSHR 
in peripheral blood in healthy volunteers and in 
benign and malignant papillary microcarcinomas 
and mRNA-TSHR correctly classified 77.8% 
of patients preoperatively (sensitivity = 76.5%; 
specificity = 79.4%). Combining mRNA-TSHR and 
US examination correctly detected 97.1% of PTMC 
and could spare surgery in 86.8% of patients with 
benign thyroid nodules [23]. Riming Liu et al. [24] 
correlated expression levels of mRNA-TSHR, and 
besides significantly higher expression of mRNA-
TSHR preoperatively in patients with papillary 
thyroid carcinoma compared to patients with benign 
nodules, they found that PTC patients’ pre-operative 
mRNA-TSHR expression level was associated with 
age, histological type, capsular invasion status, 
lymph node metastasis status, and BRAFV600E 
mutation status, but not with gender, tumor size, 
number of cancer foci, or presence of autoimmune 
thyroiditis [24].
Conclusion
Data from our research revealed a higher 
expression level of mRNA-TSHR in peripheral blood 
of TCs and TCb compared to TCr group patients. Our 
findings revealed a significant correlation between 
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mRNA-TSHR and sTg and US/WBS, or expression of 
the transcripts corresponded with clinical and laboratory 
findings in the evaluated patients. On the other hand, we 
found no significant correlation with an initial stage of 
the disease and expression levels. Further studies with 
larger number of subjects included, preoperatively and 
postoperatively, as well as absolute quantification of the 
transcripts are needed for complete understanding of 
the possible usefulness of mRNA–TSHR as a potential 
biomarker in DTCs.
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